Separately, Zacks Investment Research cut shares of Codexis from a strong-buy rating to a hold rating in a report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $20.50.
Shares of NASDAQ:CDXS opened at $15.81 on Wednesday. The company’s fifty day moving average is $14.91 and its two-hundred day moving average is $15.70. The company has a quick ratio of 7.34, a current ratio of 7.37 and a debt-to-equity ratio of 0.25. Codexis has a 12-month low of $12.68 and a 12-month high of $22.49. The company has a market cap of $911.71 million, a P/E ratio of -75.29 and a beta of -0.01.
Codexis (NASDAQ:CDXS) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.10. Codexis had a negative net margin of 17.85% and a negative return on equity of 15.24%. The company had revenue of $21.91 million for the quarter, compared to the consensus estimate of $16.56 million. Equities research analysts anticipate that Codexis will post -0.2 earnings per share for the current year.
In other news, Director Thomas R. Baruch sold 17,500 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $15.61, for a total transaction of $273,175.00. Following the transaction, the director now directly owns 90,540 shares in the company, valued at approximately $1,413,329.40. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 10.70% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Capital Investment Advisory Services LLC purchased a new position in shares of Codexis during the 2nd quarter valued at $37,000. Tower Research Capital LLC TRC purchased a new position in shares of Codexis during the 2nd quarter valued at $41,000. Quantamental Technologies LLC purchased a new position in shares of Codexis during the 2nd quarter valued at $44,000. Aperio Group LLC purchased a new position in shares of Codexis during the 2nd quarter valued at $98,000. Finally, United Capital Financial Advisers LLC purchased a new position in shares of Codexis during the 2nd quarter valued at $190,000. Institutional investors and hedge funds own 89.40% of the company’s stock.
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.
Featured Article: Book Value Per Share in Stock Trading
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.